

Emmy Boerrigter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3852089/publications.pdf>

Version: 2024-02-01

12
papers

137
citations

1684188

5
h-index

1281871

11
g-index

13
all docs

13
docs citations

13
times ranked

235
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical utility of emerging biomarkers in prostate cancer liquid biopsies. Expert Review of Molecular Diagnostics, 2020, 20, 219-230.	3.1	36
2	Management of drug-drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs. Lancet Haematology, 2022, 9, e58-e72.	4.6	29
3	Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study. Clinical Chemistry, 2020, 66, 842-851.	3.2	25
4	A Systematic Review and Meta-Analysis on the Predictive Value of Cell-Free DNA-Based Androgen Receptor Copy Number Gain in Patients With Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2020, 4, 714-729.	3.0	18
5	Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment. Molecular Oncology, 2021, 15, 2453-2465.	4.6	9
6	A non-interventional retrospective cohort study of the interaction between methotrexate and proton pump inhibitors or aspirin. Annales Pharmaceutiques Francaises, 2017, 75, 344-348.	1.0	5
7	The effect of chemotherapy on the exposure-response relation of abiraterone in metastatic castration-resistant prostate cancer. British Journal of Clinical Pharmacology, 2022, 88, 1170-1178.	2.4	5
8	RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer. Cancers, 2021, 13, 6279.	3.7	5
9	Deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapy-naïve patient: a case report. Cancer Chemotherapy and Pharmacology, 2021, 88, 165-168.	2.3	2
10	On-treatment plasma ctDNA fraction and treatment outcomes in metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, 2022, 40, 5051-5051.	1.6	2
11	Unintentional combining enzalutamide with a moderate CYP2C8 inhibitor in a patient with metastatic castration-resistant prostate cancer: a case report. Cancer Chemotherapy and Pharmacology, 2022, 89, 539.	2.3	1
12	Abstract 1413: Exploring the prognostic value of microRNAs and drug exposure in patients with metastatic castration resistant prostate cancer treated with abiraterone: a prospective observational study. , 2020, , .		0